-
The FDA has issued a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) associated with use of efalizumab (Raptiva®) for the treatment of psoriasis.
-
-
Get used to the word "pharmacogenetics" — the discipline of studying genetic variation and its effect on responses to drugs.
-
The FDA is considering new tightened restrictions on use of opioid drugs. Manufacturers of these drugs will be required to have a Risk Evaluation and Mitigation Strategy to ensure that "the benefits of the drugs continue to outweigh the risks."
-
The first new urate-lowering drug has been approved in more than 40 years.
-
-
A prospective study of men and women showed that duration of sleep is correlated with coronary artery calcification with 1 hour more of sleep daily reducing the odds of calcification over 5 years by 33%.
-
Utilizing genotyping for warfarin therapy in patients with non-valvular atrial fibrillation may not be cost-effective.
-
Proton pump inhibitors given concomitantly with clopidogrel administered after acute myocardial infarction appear to diminish the beneficial effects of clopidogrel, thus increasing the risk of re-infarction.
-
Evaluation of the clinical course of the 21,094 eligible U.S. male physicians in the Physicians' Health Study revealed that an elevated BMI in both pre-obese and obese subjects was associated with an increased risk of CHF and that vigorous physical activity was associated with a decreased risk of CHF.
